FDA clears Zynex's TensWave device for pain management [Yahoo! Finance]
Zynex, Inc. (ZYXI)
NASDAQ:AMEX Investor Relations:
zynexmed.com/ir-overview
Company Research
Source: Yahoo! Finance
The second electrotherapy device in Zynex's portfolio, the TensWave device is cleared for pain management and rehabilitation through transcutaneous electrical nerve stimulation (TENS). The US-based company was quick to note that the newer device is not intended to replace its NexWave electrotherapy device, but would provide an alternative to patients whose “insurance plans exclusively cover TENS therapy”. "We recognized a gap in the market for a high-quality TENS device that meets the specific criteria for insurance reimbursement, and TensWave is our answer to that demand,” said Zynex CEO Thomas Sandgaard. “It complements our flagship multi-modality device, the NexWave, where Interferential current is the main modality and driver of obtaining prescriptions.” The global market for neuromodulation devices was worth approximately $6.06bn in 2023 and is expected to exceed $8.9bn in 2027, as per GlobalData market analysis . Multiple companies are developing neuromodulation and TEN
Show less
Read more
Impact Snapshot
Event Time:
ZYXI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZYXI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZYXI alerts
High impacting Zynex, Inc. news events
Weekly update
A roundup of the hottest topics
ZYXI
News
- A Note On Zynex, Inc.'s (NASDAQ:ZYXI) ROE and Debt To Equity [Yahoo! Finance]Yahoo! Finance
- Zynex, Inc. (NASDAQ: ZYXI) had its price target raised by analysts at HC Wainwright from $16.00 to $17.00. They now have a "buy" rating on the stock.MarketBeat
- Zynex, Inc. (ZYXI) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Zynex Reports Third Quarter 2024 Financial ResultsPR Newswire
- Zynex Sets Third Quarter 2024 Earnings CallPR Newswire
ZYXI
Sec Filings
- 11/18/24 - Form 4
- 11/13/24 - Form 4
- 11/6/24 - Form 4
- ZYXI's page on the SEC website